Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Not always 15-20% like the high-dose clinical trials, but 5-10% is common
Phase 1: Weeks 13 (Disc Repair Priority) BPC-157: 500mcg/day subQ TB-500: 2.5mg/week subQ GHK-Cu: 1mg/day subQ Focus: disc tissue repair, nerve decompression, anti-inflammation Activity: physical therapy, gentle mobility, no loading Phase 2: Weeks 48 (Add Recomp Layer) Continue Phase 1 stack Add CJC-1295 no DAC + Ipamorelin: 100mcg each, pre-bed This layer drives GH pulsatility for tissue remodeling and begins the body recomposition phase Activity: begin light lifting as cleared by PT Phase 3: Weeks 9+ (Maintenance and Fat Loss) TB-500: Drop to maintenance 1.25mg/week BPC-157: Can drop to 250mcg/day or 5 days/week CJC+Ipa: Continue pre-bed Optional add: Tesamorelin (12mg/day, 5 days/week) for visceral fat and GH optimization pairs well with CJC+Ipa Optional add: Retatrutide for more aggressive fat loss if that's a priority What to Expect: Recovery Timeline Weeks 12: Reduced acute nerve pain is often the first noticeable change
AOD9604 is a synthetic fragment of the human growth hormone (HGH) C-terminus (176-191)
Modo de uso: Tomar 2 cpsulas con el desayuno o despus de entrenar
Wyller, V
Implications and Future Directions The pharmacy vs medical benefit structure has profound implications for patient access, health outcomes, and system costs in the context of GLP-1 drugs
